Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Beta-lapachone Highly Effective Against Non-small Cell Lung Cancer

By Biotechdaily staff writers
Posted on 18 Jul 2007
A recent report described the molecular mechanism used by the chemotherapeutic agent beta-lapachone to kill non-small cell lung cancer (NSCLC) tumors. NSCLC is one of the deadliest forms of cancer with a five-year survival rate of only about 15%.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) studied the action of beta-lapachone on the enzyme NAD(P)H:quinone oxidoreductase-1 (NQO1). NQO1 is absent or nearly absent in normal tissues but highly expressed in NSCLC tumors.

Results published in the July 3, 2007, online edition of the Proceedings of the [U.S.] National Academy of Sciences revealed that NSCLC cells grown in tissue culture were killed by a high dose of beta-lapachone given for only two to four hours. Normal cells not expressing NQO1 were not damaged by the drug.

Beta-lapachone induced formation of active radicals that caused damage to the cancer cells' DNA while at the same time disrupting the cells' ability to repair their DNA (by inhibiting the DNA repair enzyme topoisomerase I), ultimately leading to the death of the cells. Since treating tumor cells with radiation also causes DNA damage, co-treatment with radiation and beta-lapachone was even more effective than treatment with the drug alone.

"When you irradiate a tumor, the levels of NQO1 go up,” said senior author Dr. David Boothman, professor of pharmacology and radiation oncology at the University of Texas Southwestern Medical Center. "When you then treat these cells with beta-lapachone, you get synergy between the enzyme and this agent and you get a whopping kill. Basically, we have worked out the mechanism of action of beta-lapachone and devised a way of using that drug for individualized therapy.”


Related Links:
University of Texas Southwestern Medical Center

comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.